113
Oct 6 (Reuters) – Merck & Co Inc: * MERCK EXPANDS TULISOKIBART CLINICAL DEVELOPMENT PROGRAM WITH INITIATION OF PHASE 2B TRIALS IN THREE ADDITIONAL IMMUNE-MEDIATED INFLAMMATORY DISEASES * MERCK & CO INC – TRIAL MK-7240-12 FOR HIDRADENITIS SUPPURATIVA * MERCK & CO INC – TRIAL MK-7240-013 FOR AXIAL SPONDYLOARTHRITIS * MERCK & CO INC – TRIAL MK-7240-014 FOR RHEUMATOID ARTHRITIS Source text: Further company coverage: s
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
